Neurocrine Biosciences (Nasdaq: NBIX), the American biotech, has unveiled new data showing its drug Crenessity (crinecerfont) may help children and adults with classic congenital adrenal hyperplasia (CAH) achieve better hormone balance and reduce steroid use. The findings were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando.
In the Phase III studies, 90% of pediatric patients taking Crenessity hit at least one target for lowering androgen or steroid levels, compared to just 21% on placebo.
For adults, the drug also improved certain reproductive hormone levels, even as patients were able to cut back on steroid doses. In both age groups, the most common side effects included headache and fatigue, with adrenal crises rare.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze